Abstract
Cerebrospinal fluid (CSF) is being analyzed for the diagnosis of a variety of neurological diseases. Among the methods employed, metabolomics and proteomics are increasingly gaining popularity. At present, sensitivity and, in particular, specificity are limited in CSF metabolomics by nuclear magnetic resonance (NMR) spectroscopy. Nonetheless, progress is being made by studying more and more well-defined and homogeneous patient cohorts. This review starts off with a brief overview of classical CSF analysis in multiple sclerosis (MS), followed by a description of NMR spectroscopy in general metabolic CSF analysis. The subsequent sections focus on metabolomic profiling of CSF by NMR spectroscopy in MS and other neurological disorders. Currently existing results are reviewed and compared, and the potential and limits of this approach are discussed. In addition, several methodological questions are addressed, and the prospects for future developments are briefly outlined.
Keywords: Multiple sclerosis (MS), metabolomics, cerebrospinal fluid (CSF), nuclear magnetic resonance spectroscopy (NMR, MRS), neurological diseases, Cerebrospinal fluid, proteomics, homogeneous patient cohorts, multiple sclerosis, neurological disorders, biomarkers, qualitative and quantitative protein analysis, drug targets
Current Pharmaceutical Biotechnology
Title: Metabolic Profiling in Multiple Sclerosis and Other Disorders by Quantitative Analysis of Cerebrospinal Fluid Using Nuclear Magnetic Resonance Spectroscopy
Volume: 12 Issue: 7
Author(s): N. W. Lutz and P. J. Cozzone
Affiliation:
Keywords: Multiple sclerosis (MS), metabolomics, cerebrospinal fluid (CSF), nuclear magnetic resonance spectroscopy (NMR, MRS), neurological diseases, Cerebrospinal fluid, proteomics, homogeneous patient cohorts, multiple sclerosis, neurological disorders, biomarkers, qualitative and quantitative protein analysis, drug targets
Abstract: Cerebrospinal fluid (CSF) is being analyzed for the diagnosis of a variety of neurological diseases. Among the methods employed, metabolomics and proteomics are increasingly gaining popularity. At present, sensitivity and, in particular, specificity are limited in CSF metabolomics by nuclear magnetic resonance (NMR) spectroscopy. Nonetheless, progress is being made by studying more and more well-defined and homogeneous patient cohorts. This review starts off with a brief overview of classical CSF analysis in multiple sclerosis (MS), followed by a description of NMR spectroscopy in general metabolic CSF analysis. The subsequent sections focus on metabolomic profiling of CSF by NMR spectroscopy in MS and other neurological disorders. Currently existing results are reviewed and compared, and the potential and limits of this approach are discussed. In addition, several methodological questions are addressed, and the prospects for future developments are briefly outlined.
Export Options
About this article
Cite this article as:
W. Lutz N. and J. Cozzone P., Metabolic Profiling in Multiple Sclerosis and Other Disorders by Quantitative Analysis of Cerebrospinal Fluid Using Nuclear Magnetic Resonance Spectroscopy, Current Pharmaceutical Biotechnology 2011; 12 (7) . https://dx.doi.org/10.2174/138920111795909122
DOI https://dx.doi.org/10.2174/138920111795909122 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Spinal Microvascular Expression of PV-1 is Associated with Inflammation, Perivascular Astrocyte Loss, and Diminished EC Glucose Transport Potential in Acute SCI
Current Neurovascular Research Beta-Amyloid, Oxidative Stress and Down Syndrome
Current Alzheimer Research The Potential Dual Effects of Anesthetic Isoflurane on Aβ-Induced Apoptosis
Current Alzheimer Research Preface [Hot Topic: Amyloidogenic Proteins and Peptides Involved in Human Neurodegenerative Diseases (Guest Editor: Brian m. Austen)]
Protein & Peptide Letters Cerebrovascular Complications of Diabetes: SGLT-2 Inhibitors as a Promising Future Therapeutics
Current Drug Targets Microglia and Astrocytes in Alzheimer's Disease: Implications for Therapy
Current Neuropharmacology Adverse Drug Reactions Related to Drug Administration in Hospitalized Patients
Current Drug Safety Omega-3 Fatty Acids and their Role in Central Nervous System - A Review
Current Medicinal Chemistry Interplay Between Nitric Oxide and Brain-Derived Neurotrophic Factor in Neuronal Plasticity
CNS & Neurological Disorders - Drug Targets Multicomponent Reactions for Multitargeted Compounds for Alzheimer`s Disease
Current Topics in Medicinal Chemistry Serotonin (5-HT) in the Regulation of Depression-Related Emotionality: Insight from 5-HT Transporter and Tryptophan Hydroxylase-2 Knockout Mouse Models
Current Drug Targets Cardiovascular Complications of HIV Infection and Treatment
Cardiovascular & Hematological Agents in Medicinal Chemistry Nanotechnology Approaches to Target Endosomal pH: A Promising Strategy for an Efficient Intracellular Drug, Gene and Protein Delivery
Drug Delivery Letters Neurochemical and Neuropharmacological Aspects of Circadian Disruptions: An Introduction to Asynchronization
Current Neuropharmacology Quantitative Machine Learning Analysis of Brain MRI Morphology throughout Aging
Current Aging Science Altered Amplitude of Low-frequency Fluctuations in Early and Late Mild Cognitive Impairment and Alzheimer's Disease
Current Alzheimer Research Lifestyle Modifications in the Treatment of Hypertension
Current Hypertension Reviews Role of CNS Transporters in the Pharmacotherapy of HIV-1 Associated Neurological Disorders
Current Pharmaceutical Design Extrapulmonary Tuberculosis- Its Management and Control
Current Drug Therapy Butyrylcholinesterase as a Diagnostic and Therapeutic Target for Alzheimer’s Disease
Current Alzheimer Research